Trials / Completed
CompletedNCT00987337
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In Treatment-Naive, HCV Genotype 1 Infected Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) compared to peginterferon/ribavirin (pegIFN/RBV) therapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filibuvir | 300 mg BID |
| DRUG | Filibuvir | 600 mg BID |
| DRUG | Placebo | BID |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2009-09-30
- Last updated
- 2014-01-27
- Results posted
- 2014-01-27
Locations
77 sites across 9 countries: United States, Belgium, Canada, France, Germany, Hungary, Puerto Rico, South Korea, Spain
Source: ClinicalTrials.gov record NCT00987337. Inclusion in this directory is not an endorsement.